Cantor Fitzgerald set a $14.00 price objective on Strongbridge Biopharma (NASDAQ:SBBP) in a research report released on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

“Acquisition of U.S. and Canadian rights to MACRILEN, marks early start to commercialize in rare endocrine disorders.”,” Cantor Fitzgerald’s analyst wrote.

Several other analysts have also commented on the company. HC Wainwright reaffirmed a buy rating and set a $18.00 target price on shares of Strongbridge Biopharma in a report on Wednesday, November 15th. BidaskClub raised Strongbridge Biopharma from a hold rating to a buy rating in a report on Wednesday, December 27th. ValuEngine lowered Strongbridge Biopharma from a hold rating to a sell rating in a report on Monday, October 2nd. Finally, Zacks Investment Research raised Strongbridge Biopharma from a sell rating to a hold rating and set a $7.25 target price on the stock in a report on Wednesday, October 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Buy and a consensus price target of $12.81.

Shares of Strongbridge Biopharma (NASDAQ SBBP) traded up $0.70 during mid-day trading on Wednesday, hitting $8.55. The stock had a trading volume of 236,290 shares, compared to its average volume of 147,374. The company has a quick ratio of 4.61, a current ratio of 4.70 and a debt-to-equity ratio of -1.89. The firm has a market capitalization of $306.19, a price-to-earnings ratio of -2.51 and a beta of 2.60. Strongbridge Biopharma has a fifty-two week low of $2.10 and a fifty-two week high of $8.85.

Strongbridge Biopharma (NASDAQ:SBBP) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.07. equities analysts expect that Strongbridge Biopharma will post -2.86 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the stock. Caxton Corp grew its holdings in Strongbridge Biopharma by 2.2% during the third quarter. Caxton Corp now owns 5,514,994 shares of the biotechnology company’s stock worth $38,053,000 after acquiring an additional 120,000 shares during the period. Lyon Street Capital LLC acquired a new stake in Strongbridge Biopharma during the third quarter worth about $2,862,000. California State Teachers Retirement System acquired a new stake in Strongbridge Biopharma during the second quarter worth about $277,000. State Street Corp acquired a new stake in Strongbridge Biopharma during the second quarter worth about $443,000. Finally, Nexthera Capital LP acquired a new stake in Strongbridge Biopharma during the second quarter worth about $477,000. 63.96% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2018/01/21/strongbridge-biopharma-sbbp-pt-set-at-14-00-by-cantor-fitzgerald.html.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.